ArticleClinical cancer research : an official journal of the American Association for Cancer Research2017
Inhibition of Age-Related Therapy Resistance in Melanoma by Rosiglitazone-Mediated Induction of Klotho.
Open access · bronzeAbstract read
In one paragraph
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 36 citations in OpenAlex.
- Rapid activation of ARF6 after RAF inhibition augments BRAFOncogene · 2026Article
- Rapid activation of ARF6 after RAF inhibition augments BRAFV600E and promotes therapy resistance.Research square · 2025Article
- The inflection point: α-Klotho levels and the risk of all-cause mortality.Frontiers in endocrinology · 2025Article
- Age-Related Increases in IGFBP2 Increase Melanoma Cell Invasion and Lipid Synthesis.Cancer research communications · 2024Article
- Klotho Upregulation via PPARγ Contributes to the Induction of Brain Ischemic Tolerance by Cerebral Ischemic Preconditioning in Rats.Cellular and molecular neurobiology · 2023Article
- The potential therapeutic effect of klotho on cell viability in human colorectal adenocarcinoma HT-29 cells.Medical oncology (Northwood, London, England) · 2022Article
- Identification of Age-Associated Transcriptomic Changes Linked to Immunotherapy Response in Primary Melanoma.Current issues in molecular biology · 2022Article
- Modulatory effect of euxanthone in liver cancer-bearing obese mice: crosstalk between PPARγ and TIMP3 signalling axes.3 Biotech · 2021Article
- Enhancement of Apo2L/TRAIL signaling pathway receptors by the activation of Klotho gene with CRISPR/Cas9 in Caco-2 colon cancer cells.Medical oncology (Northwood, London, England) · 2021Article
- Advanced maternal age causes premature placental senescence and malformation via dysregulated α-Klotho expression in trophoblasts.Aging cell · 2021Article
- Transcription Factors: The Fulcrum Between Cell Development and Carcinogenesis.Frontiers in oncology · 2021Review
- Article
- Age-related transcriptome changes in melanoma patients with tumor-positive sentinel lymph nodes.Aging · 2020Article
- Normal Aging and Its Role in Cancer Metastasis.Cold Spring Harbor perspectives in medicine · 2020Review
- Salt causes aging-associated hypertension via vascular Wnt5a under Klotho deficiency.The Journal of clinical investigation · 2020Article
- WNT Signaling in Melanoma.International journal of molecular sciences · 2020Review
- Paradoxical Role for Wild-Type p53 in Driving Therapy Resistance in Melanoma.Molecular cell · 2020Article
- Role of Fibroblast Growth Factor 23 (FGF23) and αKlotho in Cancer.Frontiers in cell and developmental biology · 2020Review
- Polyunsaturated Fatty Acids from Astrocytes Activate PPARγ Signaling in Cancer Cells to Promote Brain Metastasis.Cancer discovery · 2019Article
- Role of Klotho in Chronic Calcineurin Inhibitor Nephropathy.Oxidative medicine and cellular longevity · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 2 institutions in 2 countries.
Reeti BeheraThe Wistar Institute, Philadelphia, Pennsylvania.
Amanpreet KaurThe Wistar Institute, Philadelphia, Pennsylvania.
Marie R WebsterThe Wistar Institute, Philadelphia, Pennsylvania.
Suyeon KimThe Wistar Institute, Philadelphia, Pennsylvania.
Abibatou NdoyeThe Wistar Institute, Philadelphia, Pennsylvania.
Curtis H KugelThe Wistar Institute, Philadelphia, Pennsylvania.
Gretchen M AliceaThe Wistar Institute, Philadelphia, Pennsylvania.
Joshua WangThe Wistar Institute, Philadelphia, Pennsylvania.
Kanad GhoshThe Wistar Institute, Philadelphia, Pennsylvania.
Phil ChengUniversity of Zurich, Zurich, Switzerland.
Sofia LisantiThe Wistar Institute, Philadelphia, Pennsylvania.
Katie MarchbankThe Wistar Institute, Philadelphia, Pennsylvania.
Vanessa DangThe Wistar Institute, Philadelphia, Pennsylvania.
Mitchell LevesqueUniversity of Zurich, Zurich, Switzerland.
Reinhard DummerUniversity of Zurich, Zurich, Switzerland.
Xiaowei XuDepartment of Pathology, University of Pennsylvania, Philadelphia, Pennsylvania.
Meenhard HerlynThe Wistar Institute, Philadelphia, Pennsylvania.
Andrew E AplinSidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania.
Alexander RoeschDepartment of Dermatology, University Hospital, West German Cancer Center, University Duesburg-Essen, Essen, Germany.
Cecilia CainoThe Wistar Institute, Philadelphia, Pennsylvania.
Dario C AltieriThe Wistar Institute, Philadelphia, Pennsylvania.
Ashani T WeeraratnaThe Wistar Institute, Philadelphia, Pennsylvania. aweeraratna@wistar.org.
University of Zurich · CHUniversity of Pennsylvania · US
Funding
Tumor Microenvironment and MetastasisP30CA010815 · NCI · WISTAR INSTITUTE · PI Luis J Montaner · 1985 to 2026
$75.9MTargeting the MAP and PI3 Kinase Pathways in MelanomaP01CA114046 · NCI · WISTAR INSTITUTE · PI WEERARATNA, ASHANI T · 2008 to 2023
$37.1M Tissue &PathologyP50CA093372 · NCI · WISTAR INSTITUTE · PI HERLYN, MEENHARD F · 2001 to 2009
$15.4MTRAINING PROGRAM IN BASIC CANCER RESEARCHT32CA009171 · NCI · WISTAR INSTITUTE · PI Alessandro Gardini · 1985 to 2026
$15.3MRole of Runx2 in prostate tumorigenesis and metastasisP01CA140043 · NCI · WISTAR INSTITUTE · PI ALTIERI, DARIO C · 2010 to 2021
$12.2MTargeted Combination Therapy for MelanomaP50CA174523 · NCI · WISTAR INSTITUTE · PI HERLYN, MEENHARD F · 2014 to 2018
$11.1MTumor PlasticityR35CA220446 · NCI · WISTAR INSTITUTE · PI ALTIERI, DARIO C · 2017 to 2023
$7.7MCONTROL OF APOPTOSIS IN CANCER BY SURVIVINR01CA078810 · NCI · YALE UNIVERSITY · PI ALTIERI, DARIO C · 1998 to 2017
$5.5MRequest for Supplemental Funds aligned to CA160495R01CA160495 · NCI · THOMAS JEFFERSON UNIVERSITY · PI APLIN, ANDREW ERIC · 2012 to 2022
$3.6MTargeted therapies in mutant BRAF melanomaR01CA182635 · NCI · THOMAS JEFFERSON UNIVERSITY · PI APLIN, ANDREW ERIC · 2014 to 2024
$3.4MPromotion of tumor invasion and pseudosenescence by the aging microenvironmentR01CA174746 · NCI · WISTAR INSTITUTE · PI WEERARATNA, ASHANI T · 2014 to 2018
$2.1M(PQC2) Plasticity Of The.PI3K Network In Early DormancyR01CA190027 · NCI · WISTAR INSTITUTE · PI ALTIERI, DARIO C · 2014 to 2016
$1.2MNCI NIH HHS K99 CA208012NCI NIH HHS P01 CA114046NCI NIH HHS P01 CA140043NCI NIH HHS P30 CA010815NCI NIH HHS P50 CA093372NCI NIH HHS P50 CA174523NCI NIH HHS R01 CA078810NCI NIH HHS R01 CA160495NCI NIH HHS R01 CA174746NCI NIH HHS R01 CA182635NCI NIH HHS R01 CA190027NCI NIH HHS R35 CA220446NCI NIH HHS T32 CA009171
Abstract
PubMed holds no abstract for this paper.
Indexed as
AdultAge FactorsAnimalsAntineoplastic Combined Chemotherapy ProtocolsCell Line, TumorCell ProliferationDrug Resistance, NeoplasmGlucuronidaseHumansIndolesKlotho ProteinsMelanomaMiceMiddle AgedMutationPPAR gammaBRAF protein, humanGlucuronidaseIndolesKlotho ProteinsPLX 4720PPAR gammaProtein Kinase InhibitorsProto-Oncogene Proteins B-rafRosiglitazoneSulfonamidesThiazolidinedionesWnt-5a ProteinWNT5A protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.